Nouscom Raises €67.5 Million ($72 Million) In Oversubscribed Series C Financing Round
Amount Raised
€67.5 Million
Round Type
Series C
BaselBiotechnologyHealth CareTherapeuticsDescription
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned international healthcare investors.
Who to call at Nouscom, and when
A new round usually means Nouscom is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nouscom raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nouscom, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nouscom. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nouscom raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Nouscom raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.